The First National Plan to Address Alzheimer's Disease was released in May of 2012 and set a blueprint for research in Alzheimer's disease (AD) to achieve the goal of effective treatment and prevention of the disease by 2025. Toward that goal, the Mayo Alzheimer's Disease Research Center (ADRC) is pursuing research to accomplish that goal. The Center will be comprised of five cores: Administrative Core to oversee the operations of the Center; Clinical Core to recruit and characterize subjects along the AD spectrum and for the AD-related dementias; Data Management and Statistical Core to collect, refine and analyze data and be compliant with the requirements of the National Alzheimer's Coordinating Center; Neuropathology Core to perform detailed neuropathological studies on autopsy specimens and disseminate genetic and other biospecimens to collaborators; Outreach, Recruitment and Education Core to assist in the recruitment and characterization of subjects for research purposes. The ADRC is also proposing three new research projects including one by a junior investigator. Project 1, Improving Clinical Prediction of Dementia Pathology and Long-Term Outcomes Using Imaging, by Prashanthi Vemuri, Ph.D., will develop a software methodology using clinical and imaging data to predict dementia subtypes; Project 2, Validating HDAC6 as a Novel Therapeutic Target for Alzheimer's Tauopathy, principal investigator Leonard Petrucelli, Ph.D., will validate inhibition of cytosolic histone deacetylase 6 that modulates the accumulation of hyperphosphorylated tau as a possible strategy for the treatment of AD; Project 3, ApoE Isoforms in Brain Vasculature and CAA, Goujun Bu, Ph.D., will investigate the roles of ApoE and ApoE receptors in the pathogenesis of AD. The ADRC will continue to maintain an active cohort of research subjects and will recruit a new cohort of at-risk subjects for Lewy body disorders. The Center will continue to serve as the nidus for AD research at the Mayo Clinic and will interact with the National Institute on Aging and other Alzheimer's Disease Centers around the country. The Center will remain flexible and adapt to new directions as the field of AD and related dementia research progresses.

Public Health Relevance

Alzheimer's disease (AD) may be the defining healthcare condition of our generation. The First Plan to Address Alzheimer's Disease for the United States was released in May of 2012 and outlined a blueprint for research and care on individuals with AD and AD-related dementias. The Mayo Alzheimer's Disease Research Center will pursue themes related to the National Plan in an attempt to have an impact on this disease within ten years.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016574-17
Application #
8838019
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Phelps, Creighton H
Project Start
1999-05-01
Project End
2019-04-30
Budget Start
2015-05-15
Budget End
2016-04-30
Support Year
17
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Sahoo, Aradhana; Bejanin, Alexandre; Murray, Melissa E et al. (2018) TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia. J Alzheimers Dis 64:1227-1233
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Pakhomov, Serguei V S; Eberly, Lynn E; Knopman, David S (2018) Recurrent perseverations on semantic verbal fluency tasks as an early marker of cognitive impairment. J Clin Exp Neuropsychol 40:832-840
Kang, Silvia S; Ebbert, Mark T W; Baker, Kelsey E et al. (2018) Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J Exp Med 215:2235-2245
Sakae, Nobutaka; Bieniek, Kevin F; Zhang, Yong-Jie et al. (2018) Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol Commun 6:63
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064

Showing the most recent 10 out of 1014 publications